Previous
Pause
Next
Skip to Navigation
↓
Publications
Year
Year
Year
-Year
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Researcher
- Any -
claramalo
usuario_prueba
Almeida e Silva, Filomena Augusta
Arenal , Raúl
Baptista , Pedro Miguel
Bernechea Navarro, María
Bover Arbós, Pere
Calvo Lacosta, Jorge Hugo
Carstensen , Hans-Heinrich
Castro Barrigón, Alberto
Cazcarro Castellano, Ignacio
Cobarrubias Baglietto, Sebastián Felipe
DeMiguel , Daniel
Domínguez Castro, Fernando
Ferrio Díaz, Juan Pedro
Gil Hernández, Vanesa
Gil Mestres, Adriá
Gracia Lostao, Ana Isabel
Gurauskis , Jonas
Hernández Ainsa, Silvia
Hernández Latas, José Antonio
Hurtado Guerrero, Ramón
Jiménez Schuhmacher, Alberto
Juarez-Perez , Emilio J.
Knoll , Fabien
Köhler , Ralf
Lopes de Sousa Martins, Pedro Alexandre
Mangas-Sánchez , Juan
Martínez Pérez, María
Martínez-Padilla , Jesús
Millán Gasca, Javier
Montiel , Manuel
Muñoz Soro, José Félix
Olmo , Jose
Ordovás Vidal, Laura
Pey Betrán, Jorge
Philippidis , George
Ramón García, Santiago
Roque , Carla
Sanz Pamplona, Rebeca
Schoorlemmer , Jon
Sola , Daniel
Stavridis , Stelios
del Río , María Pilar
Íñiguez Dieste, David
Title
Title
Year
Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains.
2013
Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled mu
2022
Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency
2020
Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria
2021
Repurposing clinically approved cephalosporins for tuberculosis therapy.
2016
Sanfetrinem, repurposing an oral beta-lactam with intracellular activity for the treatment of tuberculosis
2019
Targeting Tuberculosis: Existing drugs can - and should - be repurposed to fight neglected diseases.
2017
Targeting Tuberculosis: Existing drugs can – and should – be repurposed to fight neglected diseases.
2017
The FICI paradigm: correcting flaws in antimicrobial in vitro synergy screens at their inception.
2019
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme
2022
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening
2018
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening
2019